Interictal plasma urotensin-II concentrations in migraine and tension-type headache: a case–control biomarker study
Abstract
Abstract Objectives As our understanding of the pathophysiology of migraine continues to improve, so too do targeted treatments. It is now known that vasoactive neuropeptides, including calcitonin gene-related peptide (CGRP), play a role in migraine pathophysiology and CGRP antagonists are utilized in treatment. Urotensin II (U-II) represents the most potent vasoconstrictor peptide and research into its association with migraine remains scarce. The current study endeavors to elucidate the biochemical mechanisms which underpin migraine pathophysiology. Methods The study comprised patients suffering from migraine and tension-type headache alongside a healthy control group. The control group was selected from healthy volunteers of matching gender and age. In the interictal period, plasma samples were collected from patients with migraine and tension-type headache. The study compared plasma U-II levels of 33 migraine patients, 30 tension-type headache patients, and the control group. Results Plasma U-II levels were significantly higher in the migraine group compared to both the tension-type headache group and the control group. Furthermore, plasma U-II levels were slightly higher in the tension-type headache group than in the control group, however, a statistically significant difference was not observed. Conclusions These preliminary findings suggest that U-II may be involved in migraine pathophysiology. Higher interictal plasma U-II levels in the migraine group support further…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 33 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.